

Supplemental Table 1: Premorbid Clinical Characteristics and Therapeutics

	All (N)	COVID+ (N)	COVID- (N)
	42	22	20
Respiratory PMH	18	8	10
Cardiovascular PMH	19	11	8
Renal PMH	7	6	1
Type 2 Diabetes	20	12	8
Hypertension	24	14	10
Other comorbidities	37	18	19
Premorbid steroid used	3	1	2
Premorbid immunomodulatory medication use	2	1	1
Premorbid ACEi/ARB use	15	10	5

Abbreviations: ACEi, Angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; PMH, past medical history.

Legend: “Other comorbidities” include autoimmune diseases: Myasthenia gravis among COVID+, and autoimmune hemolytic anemia, rheumatoid arthritis and multiple sclerosis among the COVID-. No statistically significant difference between COVID+ and COVID- patients for all variables were detected using ANOVA for continuous variables and Fisher’s exact test for categorical variables at $\alpha=0.05$

Supplemental Table 2: Association between aCL IgG and high-titre anti-cytokine autoantibodies

	Cohort	All	aCL positive	aCL negative
	N	42	20	22
ALL	<i>N (%)</i>	16/42 (38%)	13/20 (65%)	3/22 (14%)
anti-GMCSF	<i>N (%)</i>	1/42 (2%)	1/20 (5%)	0/22 (0%)
anti-IFN- γ	<i>N (%)</i>	7/42 (17%)	6/20 (30%)	1/22 (5%)
anti-IL-1a	<i>N (%)</i>	1/42 (2%)	0/20 (0%)	1/22 (5%)
anti-IL-6	<i>N (%)</i>	5/42 (12%)	3/20 (15%)	2/22 (9%)
anti-IL-10	<i>N (%)</i>	5/42 (12%)	5/20 (25%)	0/22 (0%)
anti-IL-12p40	<i>N (%)</i>	2/42 (5%)	2/20 (10%)	0/22 (0%)
anti-IL-17a	<i>N (%)</i>	2/42 (5%)	2/20 (10%)	0/22 (0%)
anti-IL-17f	<i>N (%)</i>	4/42 (10%)	4/20 (20%)	0/22 (0%)
anti-IL-22	<i>N (%)</i>	1/42 (2%)	0/22 (0%)	1/22 (5%)

Abbreviations: aCL, anticardiolipin; GMCSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin.

Legend: The table reports the number of patients with high titres of anti-cytokine antibodies at any time during the first 10 days of ICU admission. “ALL” represents all patient having a high titre of anti-cytokine antibody of any type during that period. The numbers of the specific anti-cytokine antibodies sum to more than “ALL” since some patients had more than one high titre anti-cytokine antibody. Once adjusted for multiple comparisons, there were no statistically significant differences between aCL positive and aC negative- for any of the results (Fisher’s exact test at $\alpha=0.05$ followed by the false discovery rate at $q=0.05$). The following anti-cytokine AAB did not show high levels in any of the patients: anti-BAFF, anti-IFN- β , anti-TNF- α , anti-IL8, anti-IL-15 and anti-IL-18.

Supplemental Table 3: Association between aCL IgG and anti-cytokine autoantibodies per COVID-19 status

			Anti-cytokine autoantibody titers	
			Positive	High-positive
COVID ⁺	aCL IgG	<i>N</i> , %	12/13, 92%*	9/13, 69%
COVID ⁻	positive		4/7, 57%	4/7, 57%

Abbreviations: aCL, anti-cardiolipin antibodies.

Legend: The asterisk (*) represents a significant association between aCL IgG and anti-cytokine autoantibodies (Fisher's exact test, $p=0.006$, adjusted for multiple comparisons).